Melox (meloxicam) clinical efficacy in chronic joint diseases
Objective. To study efficacy and safety of Iwo doses of melox (meloxicam) in pts with rheumatoid arthritis (RA) and osteoarthritis (OA). Material and methods. An open uncontrolled study of melox was performed on 20 pts with chronic rheumatic diseases: 10 with RA and 10 with OA, 18 female and 2 male,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2003-08-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839568688460595200 |
|---|---|
| author | Sh Erdes E A Galushko T N Tsapina |
| author_facet | Sh Erdes E A Galushko T N Tsapina |
| author_sort | Sh Erdes |
| collection | DOAJ |
| description | Objective. To study efficacy and safety of Iwo doses of melox (meloxicam) in pts with rheumatoid arthritis (RA) and osteoarthritis (OA). Material and methods. An open uncontrolled study of melox was performed on 20 pts with chronic rheumatic diseases: 10 with RA and 10 with OA, 18 female and 2 male, mean age respectively 57,5±11,1 and 65,0±7,6 years, mean duration of the disease - 11,1 ±9,9 and 5,6±6,2 years. 90% of RA pis had 2nd activity degree and 1I-IV stage of the disease. 6 pts of OA group had gonarthritis and 4 - coxarthri- tis, 7 pts had 11 and 3 - 111 radiological stage according to Kellgren classification. The drug was administered orally during 4 weeks. Initial dose was 7,5 mg/day. In case of insufficient efficacy it was increased till 15 mg/day in 5 days. Results. All 20 pts completed 4-weeks study. There were no adverse events leading to withdrawal of melox. In 10 pts dose was increased from 7,5 to 15 mg/day - 2 with OA and 8 with RA. According to opinion of pts and investigators efficacy and tolerability were good or fair in 100%. Conclusion. The results of the study confirm that selective COX-2 inhibitors such as melox are effective, have good safety and usually do not cause serious adverse effects. |
| format | Article |
| id | doaj-art-bb2c3ef2b61540a29a0e3d762ff37f1d |
| institution | Matheson Library |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2003-08-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-bb2c3ef2b61540a29a0e3d762ff37f1d2025-08-04T17:03:46ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922003-08-01414717310.14412/1995-4484-2003-13381531Melox (meloxicam) clinical efficacy in chronic joint diseasesSh ErdesE A GalushkoT N TsapinaObjective. To study efficacy and safety of Iwo doses of melox (meloxicam) in pts with rheumatoid arthritis (RA) and osteoarthritis (OA). Material and methods. An open uncontrolled study of melox was performed on 20 pts with chronic rheumatic diseases: 10 with RA and 10 with OA, 18 female and 2 male, mean age respectively 57,5±11,1 and 65,0±7,6 years, mean duration of the disease - 11,1 ±9,9 and 5,6±6,2 years. 90% of RA pis had 2nd activity degree and 1I-IV stage of the disease. 6 pts of OA group had gonarthritis and 4 - coxarthri- tis, 7 pts had 11 and 3 - 111 radiological stage according to Kellgren classification. The drug was administered orally during 4 weeks. Initial dose was 7,5 mg/day. In case of insufficient efficacy it was increased till 15 mg/day in 5 days. Results. All 20 pts completed 4-weeks study. There were no adverse events leading to withdrawal of melox. In 10 pts dose was increased from 7,5 to 15 mg/day - 2 with OA and 8 with RA. According to opinion of pts and investigators efficacy and tolerability were good or fair in 100%. Conclusion. The results of the study confirm that selective COX-2 inhibitors such as melox are effective, have good safety and usually do not cause serious adverse effects.https://rsp.mediar-press.net/rsp/article/view/1594rheumatoid arthritisosteoarthritismelox (meloxicam) |
| spellingShingle | Sh Erdes E A Galushko T N Tsapina Melox (meloxicam) clinical efficacy in chronic joint diseases Научно-практическая ревматология rheumatoid arthritis osteoarthritis melox (meloxicam) |
| title | Melox (meloxicam) clinical efficacy in chronic joint diseases |
| title_full | Melox (meloxicam) clinical efficacy in chronic joint diseases |
| title_fullStr | Melox (meloxicam) clinical efficacy in chronic joint diseases |
| title_full_unstemmed | Melox (meloxicam) clinical efficacy in chronic joint diseases |
| title_short | Melox (meloxicam) clinical efficacy in chronic joint diseases |
| title_sort | melox meloxicam clinical efficacy in chronic joint diseases |
| topic | rheumatoid arthritis osteoarthritis melox (meloxicam) |
| url | https://rsp.mediar-press.net/rsp/article/view/1594 |
| work_keys_str_mv | AT sherdes meloxmeloxicamclinicalefficacyinchronicjointdiseases AT eagalushko meloxmeloxicamclinicalefficacyinchronicjointdiseases AT tntsapina meloxmeloxicamclinicalefficacyinchronicjointdiseases |